Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors Maruishi Pharmaceutical
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2017 Planned End Date changed from 30 Apr 2017 to 31 Oct 2017.
- 15 Dec 2016 Planned End Date changed from 28 Feb 2017 to 30 Apr 2017.